Synopsis
Synopsis
0
CEP/COS
0
EU WC
0
KDMF
0
VMF
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Bms-379224
1. 351227-64-0
2. Fosravuconazole [inn]
3. Bms-379224
4. Ravuconazole Phosphoester
5. Ravuconazole Methylphosphate
6. E1224 Free Acid
7. Ravuconazole Methyl Phosphate
8. E-1224 Free Acid
9. Chebi:34549
10. L4q6o5430l
11. Bms 379224
12. (((2r,3r)-3-(4-(4-cyanophenyl)thiazol-2-yl)-2-(2,4-difluorophenyl)-1-(1h-1,2,4-triazol-1-yl)butan-2-yl)oxy)methyl Dihydrogen Phosphate
13. Benzonitrile, 4-(2-((1r,2r)-2-(2,4-difluorophenyl)-1-methyl-2-((phosphonooxy)methoxy)-3-(1h-1,2,4-triazol-1-yl)propyl)-4-thiazolyl)-
14. Unii-l4q6o5430l
15. Fosravuconazole [mi]
16. Chembl333325
17. Schembl1434200
18. Fosravuconazole [who-dd]
19. Dtxsid70188627
20. Db15204
21. [(2r,3r)-3-[4-(4-cyanophenyl)-1,3-thiazol-2-yl]-2-(2,4-difluorophenyl)-1-(1,2,4-triazol-1-yl)butan-2-yl]oxymethyl Dihydrogen Phosphate
22. Hy-16779
23. Cs-0012407
24. Q27116141
25. 4-[2-[(1r,2r)-1-methyl-2-(phosphonooxymethoxy)-2-(2,4-difluorophenyl)-3-(1h-1,2,4-triazole-1-yl)propyl]thiazole-4-yl]benzonitrile
Molecular Weight | 547.5 g/mol |
---|---|
Molecular Formula | C23H20F2N5O5PS |
XLogP3 | 2.4 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 12 |
Rotatable Bond Count | 10 |
Exact Mass | 547.08908325 g/mol |
Monoisotopic Mass | 547.08908325 g/mol |
Topological Polar Surface Area | 172 Ų |
Heavy Atom Count | 37 |
Formal Charge | 0 |
Complexity | 859 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
D - Dermatologicals
D01 - Antifungals for dermatological use
D01B - Antifungals for systemic use
D01BA - Antifungals for systemic use
D01BA03 - Fosravuconazole
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Market Place
ABOUT THIS PAGE
A Fosravuconazole manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Fosravuconazole, including repackagers and relabelers. The FDA regulates Fosravuconazole manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Fosravuconazole API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Fosravuconazole manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Fosravuconazole supplier is an individual or a company that provides Fosravuconazole active pharmaceutical ingredient (API) or Fosravuconazole finished formulations upon request. The Fosravuconazole suppliers may include Fosravuconazole API manufacturers, exporters, distributors and traders.
click here to find a list of Fosravuconazole suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Fosravuconazole DMF (Drug Master File) is a document detailing the whole manufacturing process of Fosravuconazole active pharmaceutical ingredient (API) in detail. Different forms of Fosravuconazole DMFs exist exist since differing nations have different regulations, such as Fosravuconazole USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Fosravuconazole DMF submitted to regulatory agencies in the US is known as a USDMF. Fosravuconazole USDMF includes data on Fosravuconazole's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Fosravuconazole USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Fosravuconazole suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Fosravuconazole Drug Master File in Japan (Fosravuconazole JDMF) empowers Fosravuconazole API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Fosravuconazole JDMF during the approval evaluation for pharmaceutical products. At the time of Fosravuconazole JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Fosravuconazole suppliers with JDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Fosravuconazole as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Fosravuconazole API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Fosravuconazole as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Fosravuconazole and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Fosravuconazole NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Fosravuconazole suppliers with NDC on PharmaCompass.
Fosravuconazole Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Fosravuconazole GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Fosravuconazole GMP manufacturer or Fosravuconazole GMP API supplier for your needs.
A Fosravuconazole CoA (Certificate of Analysis) is a formal document that attests to Fosravuconazole's compliance with Fosravuconazole specifications and serves as a tool for batch-level quality control.
Fosravuconazole CoA mostly includes findings from lab analyses of a specific batch. For each Fosravuconazole CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Fosravuconazole may be tested according to a variety of international standards, such as European Pharmacopoeia (Fosravuconazole EP), Fosravuconazole JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Fosravuconazole USP).
LOOKING FOR A SUPPLIER?